Today, only a small percentage of patients are able to access lifesaving cell and gene therapies.
These therapies are too hard to manufacture,
Too expensive to make widely available,
And not commercially viable due to high costs, low throughput, and lack of reproducibility.
Together, we are on a mission to change that.